. home.aspx



Tetra Bio-Pharma and Ovensa Will Engage in a Collaboration to Tackle Brain Cancer

April 11, 2019 / Tetra Bio-Pharma Inc

OTTAWA, April 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that it has entered into a collaboration agreement with Ovensa Inc. ("Ovensa") to evaluate TRIOZAN™, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells. "Glioblastoma multiforme (GBM) is a common and fatal type of brain cancer and sadly took the lives of Senator John McCain and singer Gordon Downey. Our collaboration with Ovensa will evaluate if TRIOZANÔ allows a targeted delivery of cannabinoids to the brain tumor.  There is some published evidence demonstrating the activity of cannabinoids on brain tumors.  If successful this could provide an increased efficacy when this treatment is used as an adjunct to radiotherapy and or chemotherapy. This technology is also being investigated for the delivery of an antibody to the brain as part of a collaboratio...